SciVision Biotech Inc (1786) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of SciVision Biotech Inc TWD 42.09, price TWD 42.65, upside -1.3%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SciVision Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products.
Show more
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was founded in 1990 and is based in Kaohsiung, Taiwan.
Stock analysis
SciVision Biotech Inc (1786) currently trades at 42.65 TWD, while our model-based Fair Value estimate is 42.09 TWD, implying the stock looks roughly 1.3% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 53.47 TWD per share, and 8 of the 26 models we run sit above the 42.65 TWD price.
Bear case: the Growth DCF group reads lowest at 13.33 TWD, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 23.26 TWD (bear) to 61.89 TWD (bull), the price of 42.65 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
SciVision Biotech Inc reported revenue of 887M TWD in FY2025 versus 506M TWD in FY2021, a compound +15.1%/yr. Reported net income was 162M TWD in FY2025, compounding +12.4%/yr from FY2021.
Key figures
Market cap 3.6B TWD (≈ $112M) · P/E ratio 19.6 · P/S ratio 3.58 · EPS (TTM) 2.18 TWD · Dividend yield 6.6% · Net margin 18.3% · Return on equity 7.1% · Return on assets (EBIT) 8.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −1%, 1786 screens cheaper than that median.
Fair Value models
Bear 23.26 TWDFair Value 42.09 TWDBull 61.89 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.60 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.5%
Dividend (yield on the price)6.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6% vs 10%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.35% → 21%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+49.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +46.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside−1% · Above median
Profitability
Return on equity (TTM)7% · Above median
Return on assets4% · Above median
Net margin (TTM)14% · Above median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)6.6% · Top 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is SciVision Biotech Inc (1786) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 42.09 TWD versus a price of 42.65 TWD, about −1% upside (fairly valued).
What is the fair value of 1786?
Our model-based fair value for SciVision Biotech Inc is 42.09 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 42.65 TWD.
What is the quality score of 1786?
SciVision Biotech Inc has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SciVision Biotech Inc (1786)?
Our model-based price target is the fair value of 42.09 TWD (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 23.26 TWD, optimistic scenario 61.89 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the SciVision Biotech Inc stock forecast for 2026?
Our models put fair value at 42.09 TWD, about −1% upside versus a price of 42.65 TWD (fairly valued). Cautious scenario 23.26 TWD, optimistic scenario 61.89 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of SciVision Biotech Inc (1786)?
SciVision Biotech Inc reported trailing-twelve-month revenue of about 888M TWD (latest available figure, as of Sep 24, 2026).
Does SciVision Biotech Inc pay a dividend?
SciVision Biotech Inc currently shows a dividend yield of about 6.57% relative to its recent price (as of Sep 24, 2026).
What growth is priced into SciVision Biotech Inc (1786)?
For today's price to be fair in a discounted-cash-flow model, SciVision Biotech Inc would have to grow free cash flow by +49.2 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1786 use?
Our models discount SciVision Biotech Inc at 11.8 %: a base by market capitalisation (micro), damped by beta 0.40, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SciVision Biotech Inc that is +49.2 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has SciVision Biotech Inc (1786) delivered so far?
Over the past 5 years revenue at SciVision Biotech Inc grew +13.7 % a year. The price currently implies +49.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SciVision Biotech Inc (1786) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into SciVision Biotech Inc (+49.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SciVision Biotech Inc (1786)?
The free-cash-flow yield on the price is 0.73 %: that much free cash flow SciVision Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SciVision Biotech Inc (1786)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SciVision Biotech Inc it is 42.09 TWD per share (as of Sep 24, 2026), against a price of 42.65 TWD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is SciVision Biotech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1786 trades above its calculated fair value: price 42.65 TWD, fair value 42.09 TWD, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1786?
No. The price is what the market pays today (42.65 TWD); the fair value is what the company's own numbers justify (42.09 TWD). For SciVision Biotech Inc the two are 0.5600 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is SciVision Biotech Inc worth?
The market values SciVision Biotech Inc at about 3.6B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 42.65 TWD; our models calculate a fair value of 42.09 TWD per share.
What do the bullish and bearish scenarios say about 1786?
Our models span a range for SciVision Biotech Inc: cautious scenario 23.26 TWD, base 42.09 TWD, optimistic 61.89 TWD per share (as of Sep 24, 2026, price 42.65 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1786?
SciVision Biotech Inc trades at a price-to-earnings ratio of 19.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 42.09 TWD is built from several models across several years. Other multiples: P/B 1.8, P/S 4.0, EV/EBITDA 13.8.
How solid is the balance sheet of SciVision Biotech Inc (1786)?
Balance-sheet figures for SciVision Biotech Inc (as of Sep 24, 2026): return on equity 7.1%, debt of 0.19 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 1786 from its 52-week high?
SciVision Biotech Inc trades at 42.65 TWD, about 61% below its 52-week high of 110.50 TWD and at the low of 42.65 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 42.09 TWD is for.
Which stocks are comparable to SciVision Biotech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SciVision Biotech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 42.65 TWD, calculated fair value 42.09 TWD (−1%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1786 calculated?
We run SciVision Biotech Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 42.09 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. SciVision Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SciVision Biotech Inc (1786)?
The closing price on Sep 24, 2026 was 42.65 TWD. Our model-based fair value is 42.09 TWD, about −1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SciVision Biotech Inc right now?
The model range is unusually wide (23.26 TWD to 61.89 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Key figures of SciVision Biotech Inc
How large is the market capitalisation of SciVision Biotech Inc (1786)?
The market capitalisation of SciVision Biotech Inc is 3.6B TWD (≈ $112M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SciVision Biotech Inc (1786)?
The price-to-sales ratio of SciVision Biotech Inc is 3.58 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SciVision Biotech Inc (1786)?
Earnings per share at SciVision Biotech Inc are 2.18 TWD (price ÷ EPS = P/E 19.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SciVision Biotech Inc (1786)?
The dividend yield of SciVision Biotech Inc is 6.6% (payout 129%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SciVision Biotech Inc (1786)?
The net margin of SciVision Biotech Inc is 18.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SciVision Biotech Inc (1786)?
The return on equity (ROE) of SciVision Biotech Inc is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SciVision Biotech Inc (1786)?
On an EBIT basis the return on assets of SciVision Biotech Inc is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SciVision Biotech Inc (1786)?
The operating margin of SciVision Biotech Inc is 10.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SciVision Biotech Inc (1786)?
Revenue at SciVision Biotech Inc is growing +0.5% versus a year earlier (3y avg +16.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SciVision Biotech Inc (1786)?
Earnings per share at SciVision Biotech Inc are growing −62.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does SciVision Biotech Inc (1786) hold?
SciVision Biotech Inc holds more cash than debt, 361M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch SciVision Biotech Inc in the live analysis
One click puts SciVision Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
